[go: up one dir, main page]

WO2009038411A3 - Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety - Google Patents

Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety Download PDF

Info

Publication number
WO2009038411A3
WO2009038411A3 PCT/KR2008/005592 KR2008005592W WO2009038411A3 WO 2009038411 A3 WO2009038411 A3 WO 2009038411A3 KR 2008005592 W KR2008005592 W KR 2008005592W WO 2009038411 A3 WO2009038411 A3 WO 2009038411A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
dihydro
oxo
inhibiting compounds
pyrazole moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2008/005592
Other languages
French (fr)
Other versions
WO2009038411A2 (en
Inventor
Hyo-Shin Kwak
Hyejin Jung
Kyeongsik Min
Heuisul Park
Deog-Young Choi
Dongchul Lim
Jae-Ung Choi
Mijeong Park
Hyunjung Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Publication of WO2009038411A2 publication Critical patent/WO2009038411A2/en
Publication of WO2009038411A3 publication Critical patent/WO2009038411A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed are compounds represented by Formula (I) as defined in the specification, or pharmaceutically acceptable salts or isomers thereof, and a pharmaceutical composition for inhibiting beta-secretase activity comprising a therapeutically effective amount of the same.
PCT/KR2008/005592 2007-09-21 2008-09-22 Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety Ceased WO2009038411A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070096504 2007-09-21
KR10-2007-0096504 2007-09-21

Publications (2)

Publication Number Publication Date
WO2009038411A2 WO2009038411A2 (en) 2009-03-26
WO2009038411A3 true WO2009038411A3 (en) 2009-05-07

Family

ID=40468634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/005592 Ceased WO2009038411A2 (en) 2007-09-21 2008-09-22 Beta-secretase inhibiting compounds having oxo-dihydro-pyrazole moiety

Country Status (2)

Country Link
KR (1) KR20090031331A (en)
WO (1) WO2009038411A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102212012A (en) * 2010-04-12 2011-10-12 上海源力生物技术有限公司 Intermediate for synthesizing aliskiren and preparation method thereof
BR112016017781A2 (en) 2014-02-14 2017-08-08 Inception 2 Inc PYRAZOLONE COMPOUNDS AND USES THEREOF
CN108997242B (en) * 2018-07-28 2020-10-20 浙江大学 Substituted phenyl pyrazolone derivative, preparation and application
JP2023137325A (en) * 2022-03-18 2023-09-29 日清食品ホールディングス株式会社 Method for producing 2-acetyl-1-pyrroline

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006021A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzh eimer's disease
WO2005087215A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
WO2007047306A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006021A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzh eimer's disease
US20030083356A1 (en) * 2001-07-10 2003-05-01 Schostarez Heinrich Josef Statine derivatives for the treatment of Alzheimer's disease
WO2005087215A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
WO2007047306A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors

Also Published As

Publication number Publication date
WO2009038411A2 (en) 2009-03-26
KR20090031331A (en) 2009-03-25

Similar Documents

Publication Publication Date Title
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2007135527A3 (en) Benzimidazolyl compounds
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2008096001A8 (en) Hcv inhibiting macrocyclic phenylcarbamates
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2007117465A3 (en) Indazole compounds
MX2009012285A (en) Diacylglycerol acyltransferase inhibitors.
WO2007084728A3 (en) 2-imino-benzimidazoles
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
WO2007126900A3 (en) Antifungal agents
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
MX2009003081A (en) Pyrrole derivatives useful for the treatment of cytokine-mediated diseases.
TN2010000038A1 (en) Organic compounds
WO2008006795A3 (en) Indole compounds
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
WO2008143649A3 (en) Novel oxazolidinone compounds as antiinfective agents
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2008000421A3 (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08832052

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08832052

Country of ref document: EP

Kind code of ref document: A2